Treatment Information

Back

Ovarian Cancer treatment details. Biologic therapy, Immunotherapy.

Vancover Cancer Center, Vancouver, Canada.

Survival: monthsCountry:Canada
Toxiciy Grade:3City/State/Province:Vancouver
Treatments:Biologic therapy, ImmunotherapyHospital:Vancover Cancer Center
Drugs:Journal:Link
Date:Nov 2005

Description:

Patients: This pilot phase II study involved thirteen women with a mean age of 59.1 with recurrent stage III or IV ovarian cancer. Those enrolled in the study had an average of 2.5 prior chemotherapy treatments with a median time from primary chemotherapy treatment of 2.5 months.

Treatment: Patients received two to nine doses of orgovomab (a monoclonal antibody that is directed against a well known ovarian cancer marker that is elevated in nearly all patients with late stage ovarian cancer).

Toxicity: Grade 3 backpain, chills, rash and headache.

Results: There were no complete or partial responses to this treatment and median survival was 8.5 months.

Correspondence: Thomas G. Ehlen, M.D.



Back